ORIGINAL
Radioinmunoterapia en el linfoma no Hodgkin, posicionamiento, seguridad y eficacia de 90Y-ibritumomab. Experiencia y seguimiento a los 10 años
Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up
Leído
2383
Vecesse ha leído el artículo
1857
Total PDF
526
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 8 | 8 |
| 2025 11 | 0 | 42 | 42 |
| 2025 10 | 0 | 18 | 18 |
| 2025 9 | 0 | 30 | 30 |
| 2025 8 | 0 | 26 | 26 |
| 2025 7 | 0 | 17 | 17 |
| 2025 6 | 1 | 19 | 20 |
| 2025 5 | 0 | 21 | 21 |
| 2025 4 | 0 | 20 | 20 |
| 2025 3 | 2 | 28 | 30 |
| 2025 2 | 0 | 66 | 66 |
| 2025 1 | 1 | 106 | 107 |
| 2024 12 | 0 | 25 | 25 |
| 2024 11 | 0 | 28 | 28 |
| 2024 10 | 1 | 31 | 32 |
| 2024 9 | 0 | 24 | 24 |
| 2024 8 | 0 | 19 | 19 |
| 2024 7 | 0 | 19 | 19 |
| 2024 6 | 0 | 14 | 14 |
| 2024 5 | 0 | 25 | 25 |
| 2024 4 | 0 | 23 | 23 |
| 2024 3 | 0 | 13 | 13 |
| 2024 2 | 3 | 44 | 47 |
| 2024 1 | 1 | 63 | 64 |
| 2023 12 | 3 | 23 | 26 |
| 2023 11 | 0 | 35 | 35 |
| 2023 10 | 3 | 29 | 32 |
| 2023 9 | 0 | 19 | 19 |
| 2023 8 | 0 | 16 | 16 |
| 2023 7 | 0 | 14 | 14 |
| 2023 6 | 0 | 38 | 38 |
| 2023 5 | 0 | 36 | 36 |
| 2023 4 | 1 | 46 | 47 |
| 2023 3 | 1 | 42 | 43 |
| 2023 2 | 0 | 43 | 43 |
| 2022 1 | 0 | 13 | 13 |
| 2022 12 | 0 | 12 | 12 |
| 2022 11 | 0 | 21 | 21 |
| 2022 10 | 2 | 18 | 20 |
| 2022 9 | 0 | 32 | 32 |
| 2022 8 | 0 | 16 | 16 |
| 2022 7 | 0 | 23 | 23 |
| 2022 6 | 0 | 13 | 13 |
| 2022 5 | 0 | 18 | 18 |
| 2022 4 | 0 | 18 | 18 |
| 2022 3 | 4 | 35 | 39 |
| 2022 2 | 2 | 29 | 31 |
| 2021 1 | 12 | 31 | 43 |
| 2021 12 | 1 | 27 | 28 |
| 2021 11 | 2 | 22 | 24 |
| 2021 10 | 4 | 18 | 22 |
| 2021 9 | 112 | 29 | 141 |
| 2021 8 | 0 | 26 | 26 |
| 2021 7 | 0 | 15 | 15 |
| 2021 6 | 7 | 12 | 19 |
| 2021 5 | 0 | 18 | 18 |
| 2021 4 | 0 | 13 | 13 |
| 2021 3 | 12 | 32 | 44 |
| 2021 2 | 0 | 5 | 5 |
| 2020 1 | 0 | 7 | 7 |
| 2020 12 | 2 | 9 | 11 |
| 2020 11 | 0 | 6 | 6 |
| 2020 10 | 0 | 3 | 3 |
| 2020 9 | 0 | 9 | 9 |
| 2020 7 | 2 | 9 | 11 |
| 2020 6 | 0 | 9 | 9 |
| 2020 5 | 0 | 6 | 6 |
| 2020 4 | 1 | 8 | 9 |
| 2020 3 | 0 | 3 | 3 |
| 2020 2 | 0 | 3 | 3 |
| 2020 1 | 1 | 6 | 7 |
| 2019 12 | 0 | 7 | 7 |
| 2019 11 | 1 | 15 | 16 |
| 2019 10 | 0 | 6 | 6 |
| 2019 9 | 0 | 9 | 9 |
| 2019 8 | 1 | 6 | 7 |
| 2019 7 | 0 | 5 | 5 |
| 2019 4 | 0 | 2 | 2 |
| 2019 3 | 2 | 4 | 6 |
| 2019 1 | 107 | 57 | 164 |
| 2018 12 | 38 | 28 | 66 |
| 2018 11 | 18 | 14 | 32 |
| 2018 10 | 38 | 26 | 64 |
| 2018 9 | 27 | 14 | 41 |
| 2018 8 | 12 | 0 | 12 |
| 2018 7 | 19 | 0 | 19 |
| 2018 6 | 20 | 2 | 22 |
| 2018 5 | 15 | 0 | 15 |
| 2018 4 | 0 | 1 | 1 |
| 2018 3 | 2 | 0 | 2 |
| 2018 2 | 12 | 2 | 14 |
| 2018 1 | 15 | 1 | 16 |
| 2017 12 | 1 | 0 | 1 |
| 2017 10 | 1 | 1 | 2 |
| 2017 8 | 1 | 2 | 3 |
| 2017 6 | 1 | 0 | 1 |
| 2017 5 | 1 | 0 | 1 |
| 2017 3 | 1 | 1 | 2 |
| 2017 2 | 5 | 1 | 6 |
| 2016 1 | 7 | 4 | 11 |
| 2016 12 | 0 | 2 | 2 |
| 2016 8 | 0 | 2 | 2 |
| 2016 7 | 0 | 1 | 1 |
Mostrar todo
